
Benjamin P. Blumel
Examiner (ID: 13928, Phone: (571)272-4960 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1671 |
| Total Applications | 1338 |
| Issued Applications | 802 |
| Pending Applications | 145 |
| Abandoned Applications | 411 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18197327
[patent_doc_number] => 20230050846
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => TREATMENT OF HEPATIC AND CARDIOVASCULAR DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/786124
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15810
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786124
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/786124 | TREATMENT OF HEPATIC AND CARDIOVASCULAR DISORDERS | Dec 17, 2020 | Pending |
Array
(
[id] => 18184779
[patent_doc_number] => 20230045509
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR
[patent_app_type] => utility
[patent_app_number] => 17/756971
[patent_app_country] => US
[patent_app_date] => 2020-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17756971
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/756971 | PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR | Dec 6, 2020 | Abandoned |
Array
(
[id] => 18141460
[patent_doc_number] => 20230015302
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => METHODS FOR IDENTIFYING VIRAL INFECTIONS AND FOR ANALYZING EXOSOMES IN LIQUID SAMPLES BY RAMAN SPECTROSCOPY
[patent_app_type] => utility
[patent_app_number] => 17/782951
[patent_app_country] => US
[patent_app_date] => 2020-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32006
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782951
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782951 | METHODS FOR IDENTIFYING VIRAL INFECTIONS AND FOR ANALYZING EXOSOMES IN LIQUID SAMPLES BY RAMAN SPECTROSCOPY | Dec 3, 2020 | Abandoned |
Array
(
[id] => 17873753
[patent_doc_number] => 11445742
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => Coated egg yolk cores, methods of making and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/110585
[patent_app_country] => US
[patent_app_date] => 2020-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 4498
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110585
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/110585 | Coated egg yolk cores, methods of making and methods of use thereof | Dec 2, 2020 | Issued |
Array
(
[id] => 18179546
[patent_doc_number] => 20230040275
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/777954
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24410
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -78
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777954
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/777954 | SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS | Nov 18, 2020 | Pending |
Array
(
[id] => 18831937
[patent_doc_number] => 20230400464
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => METHOD FOR ASSESSING THE SEVERITY OF SARS
[patent_app_type] => utility
[patent_app_number] => 18/251321
[patent_app_country] => US
[patent_app_date] => 2020-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2295
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251321
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/251321 | METHOD FOR ASSESSING THE SEVERITY OF SARS | Nov 2, 2020 | Pending |
Array
(
[id] => 18075964
[patent_doc_number] => 20220401576
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => GOLD NANOPARTICLES/NANOSHELLS IMMUNE CONJUGATES FOR ENHANCED IMMUNOTHERAPY AND PHOTOTHERMAL THERAPY FOR HEMATOLOGIC MALIGNANCIES
[patent_app_type] => utility
[patent_app_number] => 17/773519
[patent_app_country] => US
[patent_app_date] => 2020-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773519
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/773519 | GOLD NANOPARTICLES/NANOSHELLS IMMUNE CONJUGATES FOR ENHANCED IMMUNOTHERAPY AND PHOTOTHERMAL THERAPY FOR HEMATOLOGIC MALIGNANCIES | Nov 1, 2020 | Pending |
Array
(
[id] => 18013315
[patent_doc_number] => 11505597
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/082865
[patent_app_country] => US
[patent_app_date] => 2020-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 22080
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17082865
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/082865 | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof | Oct 27, 2020 | Issued |
Array
(
[id] => 16778418
[patent_doc_number] => 20210115496
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => Methods and Devices for Real-Time Diagnostic Testing (RDT) for Ebola and other Infectious Diseases
[patent_app_type] => utility
[patent_app_number] => 17/067257
[patent_app_country] => US
[patent_app_date] => 2020-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29970
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067257
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/067257 | Methods and Devices for Real-Time Diagnostic Testing (RDT) for Ebola and other Infectious Diseases | Oct 8, 2020 | Abandoned |
Array
(
[id] => 16726536
[patent_doc_number] => 20210093683
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => HERPES 2 ANTIBODY SYSTEM
[patent_app_type] => utility
[patent_app_number] => 17/063715
[patent_app_country] => US
[patent_app_date] => 2020-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3276
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063715
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/063715 | HERPES 2 ANTIBODY SYSTEM | Oct 4, 2020 | Abandoned |
Array
(
[id] => 16748848
[patent_doc_number] => 20210100857
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => HERPES 1 ANTIBODY SYSTEM
[patent_app_type] => utility
[patent_app_number] => 17/063706
[patent_app_country] => US
[patent_app_date] => 2020-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3189
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063706
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/063706 | HERPES 1 ANTIBODY SYSTEM | Oct 4, 2020 | Abandoned |
Array
(
[id] => 18071432
[patent_doc_number] => 11530255
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-20
[patent_title] => Human antibodies to Ebola virus glycoprotein
[patent_app_type] => utility
[patent_app_number] => 17/039557
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 28474
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 383
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039557
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/039557 | Human antibodies to Ebola virus glycoprotein | Sep 29, 2020 | Issued |
Array
(
[id] => 18825439
[patent_doc_number] => 11840710
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-12
[patent_title] => Methods for purification of recombinant AAV vectors
[patent_app_type] => utility
[patent_app_number] => 17/035480
[patent_app_country] => US
[patent_app_date] => 2020-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 19198
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17035480
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/035480 | Methods for purification of recombinant AAV vectors | Sep 27, 2020 | Issued |
Array
(
[id] => 17983853
[patent_doc_number] => 20220349889
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => IMMUNOASSAY FOR HEPATITIS B VIRUS CORE-RELATED ANTIGEN AND KIT THEREFOR
[patent_app_type] => utility
[patent_app_number] => 17/763687
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12625
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763687
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/763687 | IMMUNOASSAY FOR HEPATITIS B VIRUS CORE-RELATED ANTIGEN AND KIT THEREFOR | Sep 24, 2020 | Pending |
Array
(
[id] => 17990501
[patent_doc_number] => 20220356538
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => HEPATITIS B VIRUS MUTANTS WITH INCREASED COVALENTLY CLOSED CIRCULAR DNA
[patent_app_type] => utility
[patent_app_number] => 17/763109
[patent_app_country] => US
[patent_app_date] => 2020-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7915
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763109
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/763109 | HEPATITIS B VIRUS MUTANTS WITH INCREASED COVALENTLY CLOSED CIRCULAR DNA | Sep 22, 2020 | Pending |
Array
(
[id] => 16704369
[patent_doc_number] => 10954289
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-03-23
[patent_title] => Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
[patent_app_type] => utility
[patent_app_number] => 17/021286
[patent_app_country] => US
[patent_app_date] => 2020-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 17
[patent_no_of_words] => 45362
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17021286
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/021286 | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments | Sep 14, 2020 | Issued |
Array
(
[id] => 17858564
[patent_doc_number] => 11439702
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-13
[patent_title] => Influenza peptides and compositions
[patent_app_type] => utility
[patent_app_number] => 17/013000
[patent_app_country] => US
[patent_app_date] => 2020-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 12
[patent_no_of_words] => 18504
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 272
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17013000
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/013000 | Influenza peptides and compositions | Sep 3, 2020 | Issued |
Array
(
[id] => 16671389
[patent_doc_number] => 20210060152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => MULTIPLE MOSQUITO-BORNE FLAVIVIRUS VACCINE AND USE THEREOF IN INDUCING NEUTRALIZING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/011140
[patent_app_country] => US
[patent_app_date] => 2020-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1919
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011140
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/011140 | MULTIPLE MOSQUITO-BORNE FLAVIVIRUS VACCINE AND USE THEREOF IN INDUCING NEUTRALIZING ANTIBODIES | Sep 2, 2020 | Abandoned |
Array
(
[id] => 16720110
[patent_doc_number] => 20210087257
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/011934
[patent_app_country] => US
[patent_app_date] => 2020-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24038
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011934
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/011934 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF | Sep 2, 2020 | Abandoned |
Array
(
[id] => 17865408
[patent_doc_number] => 20220288143
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS
[patent_app_type] => utility
[patent_app_number] => 17/638750
[patent_app_country] => US
[patent_app_date] => 2020-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19690
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638750
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/638750 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS | Aug 30, 2020 | Pending |